0000000000991372

AUTHOR

Ricard Borrás

showing 1 related works from this author

Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer

2018

The availability of biologicals, such as anti-EFGR and anti-VEGF antibodies in combination with chemotherapy (ChT), has improved prognosis of metastatic colorectal cancer (mCRC). However, the administration of drug combinations for a prolonged time implies an increased rate of toxicities, which is why some strategies to de-escalate treatment intensity have been studied.

OncologyDrugmedicine.medical_specialtyChemotherapybiologyBevacizumabbusiness.industryColorectal cancermedicine.medical_treatmentmedia_common.quotation_subjectmedicine.diseaseDisease controlText miningEditorialInternal medicinebiology.proteinMedicineSingle agentAntibodybusinessmedia_commonmedicine.drug
researchProduct